Hang Xie

InstitutionShanghai Institute of Materia Medica
AddressShanghai
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 7 Covid-19 publications, with a maximum of 3 publications in April 2021
    All Publications
    Bar chart showing 58 publications over 20 distinct years, with a maximum of 9 publications in 2017
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Su H, Yao S, Zhao W, Zhang Y, Liu J, Shao Q, Wang Q, Li M, Xie H, Shang W, Ke C, Feng L, Jiang X, Shen J, Xiao G, Jiang H, Zhang L, Ye Y, Xu Y. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun. 2021 06 15; 12(1):3623. PMID: 34131140.
      Citations: 7     Fields:    Translation:HumansCells
    2. Wan XF, Tang CY, Ritter D, Wang Y, Li T, Segovia K, Kosikova M, Johnson M, Kwon HJ, Xie H, Hammer RD, McElroy JA, Hamid A, Collins ND, Hang J, Camp S. SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing. J Med Virol. 2021 07; 93(7):4570-4575. PMID: 33830520.
      Citations: 4     Fields:    Translation:Humans
    3. Dai W, Jochmans D, Xie H, Yang H, Li J, Su H, Chang D, Wang J, Peng J, Zhu L, Nian Y, Hilgenfeld R, Jiang H, Chen K, Zhang L, Xu Y, Neyts J, Liu H. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. J Med Chem. 2022 02 24; 65(4):2794-2808. PMID: 33872498.
      Citations: 2     Fields:    
    4. Plant EP, Xie H. Research Updates for Influenza Virus and Vaccine Development. Vaccines (Basel). 2021 Apr 14; 9(4). PMID: 33919751.
      Citations:    
    5. Guo S, Xie H, Lei Y, Liu B, Zhang L, Xu Y, Zuo Z. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation. Bioorg Chem. 2021 05; 110:104767. PMID: 33667900.
      Citations: 4     Fields:    Translation:Humans
    6. Xiong M, Su H, Zhao W, Xie H, Shao Q, Xu Y. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design. Med Res Rev. 2021 07; 41(4):1965-1998. PMID: 33460213.
      Citations: 9     Fields:    Translation:HumansCells
    7. Su HX, Yao S, Zhao WF, Li MJ, Liu J, Shang WJ, Xie H, Ke CQ, Hu HC, Gao MN, Yu KQ, Liu H, Shen JS, Tang W, Zhang LK, Xiao GF, Ni L, Wang DW, Zuo JP, Jiang HL, Bai F, Wu Y, Ye Y, Xu YC. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020 Sep; 41(9):1167-1177. PMID: 32737471.
      Citations: 79     Fields:    Translation:HumansAnimalsCellsPHPublic Health